Compare PLRX & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLRX | QSI |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | 49 | 145 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 191.6M |
| IPO Year | 2020 | N/A |
| Metric | PLRX | QSI |
|---|---|---|
| Price | $1.16 | $0.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $2.67 | $1.00 |
| AVG Volume (30 Days) | 620.5K | ★ 4.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $618.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.08 | $0.69 |
| 52 Week High | $1.95 | $3.10 |
| Indicator | PLRX | QSI |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 38.01 |
| Support Level | $1.12 | $0.69 |
| Resistance Level | $1.37 | $1.04 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 78.70 | 9.23 |
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.